Prevention of emesis by ics 205-930 in children receiving cytotoxic chemotherapy

This publication has 11 references indexed in Scilit:

• Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients
  European Journal of Cancer and Clinical Oncology, 1991
• 5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.
  Archives of Disease in Childhood, 1990
• Antiemetic therapy for chemotherapy-induced vomiting: Metoclopramide, benztropine, dexamethasone, and lorazepam regimen compared with chlorpromazine alone
  The Journal of Pediatrics, 1989
• 5‐HT₃ receptor antagonists injected into the area postrema inhibit cisplatin‐induced emesis in the ferret
  British Journal of Pharmacology, 1989
• The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694
  British Journal of Cancer, 1988
• Neuropharmacology of emesis induced by anti-cancer therapy
  Trends in Pharmacological Sciences, 1988
• The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride
  Journal of Pharmacy and Pharmacology, 1988
• Antiemetic properties of the 5HT3-receptor antagonist, gr38032f
  Cancer Treatment Reviews, 1987
• FIRST RESULTS WITH ICS 205-930 (5-HT3 RECEPTOR ANTAGONIST) IN PREVENTION OF CHEMOTHERAPY-INDUCED EMESIS
  The Lancet, 1987
• Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy.
  Journal of Clinical Oncology, 1985